Baseline IL-6 is a biomarker for unfavourable tuberculosis treatment outcomes: a multisite discovery and validation study
Akshay N. Gupte, Pavan Kumar, Mariana Araújo-Pereira, Vandana Kulkarni, Mandar Paradkar, Neeta Pradhan, Pradeep Menon, Chandrasekaran Padmapriyadarsini, Luke-Elizabeth Hanna, Shri Vijay Bala Yogendra Shivakumar, Neesha Rockwood, Elsa Du Bruyn, Rajesh Karyakarte, Sanjay Gaikwad, Robert Bollinger, Jonathan Golub, Nikhil Gupte, Vijay Viswanathan, Robert J. Wilkinson, Vidya Mave, Subash Babu, Hardy Kornfeld, Bruno B. Andrade, Amita Gupta
Source: Eur Respir J, 59 (4) 2100905; 10.1183/13993003.00905-2021
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Akshay N. Gupte, Pavan Kumar, Mariana Araújo-Pereira, Vandana Kulkarni, Mandar Paradkar, Neeta Pradhan, Pradeep Menon, Chandrasekaran Padmapriyadarsini, Luke-Elizabeth Hanna, Shri Vijay Bala Yogendra Shivakumar, Neesha Rockwood, Elsa Du Bruyn, Rajesh Karyakarte, Sanjay Gaikwad, Robert Bollinger, Jonathan Golub, Nikhil Gupte, Vijay Viswanathan, Robert J. Wilkinson, Vidya Mave, Subash Babu, Hardy Kornfeld, Bruno B. Andrade, Amita Gupta. Baseline IL-6 is a biomarker for unfavourable tuberculosis treatment outcomes: a multisite discovery and validation study. Eur Respir J, 59 (4) 2100905; 10.1183/13993003.00905-2021
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|